Calyxt, Inc. — Form 10-Q Summary
Filing-identity note: The request identifies Cibus, Inc., but the supplied filing is for Calyxt, Inc. (NASDAQ: CLXT). This summary reflects the filing provided. It covers the quarter ended March 31, 2021, compared with the quarter ended March 31, 2020; balance-sheet comparisons are to December 31, 2020.
Business context and reporting period
Calyxt is an agricultural biotechnology company using gene-editing technology to develop plant traits and products. It reported eight projects in later-stage development, including two in Phase 3, and said it would prioritize trait development and licensing to partners over direct commercialization. Cellectis owned 64.5% of its common stock as of March 31, 2021.
Financial performance and liquidity
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | $4.4 million | $2.4 million |
| Cost of goods sold | $6.7 million | $3.9 million |
| Gross margin | $(2.3) million; (53)% | $(1.5) million; (63)% |
| Operating expenses | $7.3 million | $9.1 million |
| Net loss | $(10.0) million | $(11.1) million |
| Net loss per share | $(0.27) | $(0.34) |
| Net cash used in operating activities | $(9.4) million | $(12.2) million |
Revenue increased 85%, driven by sales of the 2020 grain crop; the comparable 2020 quarter included oil and meal sales instead. Cost of goods sold rose 74%, reflecting higher sales volume, higher soybean commodity costs, and unrealized hedge losses. Management cited a non-GAAP adjusted gross margin of $(1.3) million, or (31)%, versus $(1.2) million, or (49)%, a year earlier. Adjusted EBITDA loss was $6.8 million versus $8.2 million.
At March 31, 2021, cash and cash equivalents were $16.4 million, short-term investments $3.0 million, and restricted cash $1.0 million, for $20.4 million in total. Current liabilities were $6.3 million. The company reported $17.8 million of financing lease obligations and $1.5 million of long-term debt, the latter being a Paycheck Protection Program (PPP) loan. On April 8, 2021, the SBA notified Calyxt that the PPP loan and accrued interest had been forgiven; the company expected to recognize the resulting income in Q2 2021. Management believed available cash, investments, and restricted cash would fund operations into the second half of 2022.
Total assets were $52.4 million, down from $63.3 million at year-end 2020; stockholders’ equity was $25.6 million, down from $36.9 million. Cash, cash equivalents, and restricted cash decreased by $0.9 million during the quarter. Investing activities provided $8.4 million, mainly from net sales of short-term investments.
Material changes and unusual items
- Management shifted its baseline strategy toward developing traits and licensing them to partners, aiming to reduce capital needs and downstream commercialization costs. It planned to transition its existing high-oleic soybean product to licensing in 2022 and was discussing potential licensing partners.
- Development of an improved-oil HOLL soybean product was discontinued during the quarter. The company reported successful completion of hemp genome transformation and a new seed-sale agreement with an affiliate of an existing grain customer.
- CEO James Blome left on February 19, 2021. Calyxt recorded $2.3 million of cash separation expense, payable over 24 months beginning March 2021, and a $0.1 million non-cash charge for accelerated recognition of prior sign-on bonus expense. Forfeiture of his unvested awards generated a $2.5 million non-cash stock-compensation benefit. The filing attributes lower SG&A in part to this recapture, while officer-transition costs partly offset the savings.
- Noncancelable commitments to purchase grain and seed totaled $11.7 million at March 31, 2021, down from $21.2 million disclosed previously; these commitments were not recorded as liabilities because delivery had not occurred.
Outlook, risks, and contingencies
Calyxt expected operating losses to continue for several years and said R&D would be its primary area of expense growth as it advances its pipeline. It expected SG&A to decline as its streamlined model is implemented and projected lower operating cash use in the remainder of 2021 than in 2020. It cautioned that additional capital may be needed and may not be available on acceptable terms; insufficient funding could force delays, reductions, or discontinuation of development or commercialization. Management said COVID-19 had not materially affected Q1 operations, but continued uncertainty could disrupt operations and make financing more difficult. Other disclosed risks include regulatory costs, crop and field-trial outcomes, commodity prices, customer and market acceptance, partner execution, supply-chain disruptions, and intellectual-property challenges. The company reported no material pending legal proceedings and no material changes to its previously disclosed risk factors.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Calyxt, Inc., not Cibus, Inc.
- Track cash burn and financing needs against management’s stated runway into the second half of 2022.
- Assess whether licensing discussions and the revised commercialization strategy lead to partner agreements, milestones, or royalties.
- Monitor grain-sale margins, inventory valuation adjustments, and commodity hedges; reported GAAP gross margin remained negative.
- Verify the Q2 accounting treatment and recognized amount for PPP forgiveness, and track the remaining CEO separation payments.
- Follow clinical-style development milestones, regulatory progression, and the stated planting timelines for pipeline products.